Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Entero Therapeutics ( (ENTO) ) is now available.
On October 1, 2025, Entero Therapeutics announced the acquisition of GRID AI Corp, a grid-edge AI platform, marking a strategic entry into the AI energy-infrastructure market. This transaction is expected to enhance Entero’s market positioning by leveraging GRID AI’s technology to address the growing power demands from AI-driven data centers and integrate renewable energy solutions. The acquisition will result in former GRID AI shareholders owning approximately 82.5% of Entero’s common stock, and the company plans to operate GRID AI as a wholly owned subsidiary. This move aligns Entero with the increasing investments in AI infrastructure and positions it to benefit from the sector’s growth.
More about Entero Therapeutics
Entero Therapeutics is a publicly listed company on Nasdaq, primarily focused on developing targeted, non-systemic therapies for gastrointestinal diseases. The company’s key product is Adrulipase, a recombinant lipase enzyme aimed at aiding digestion in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following the acquisition of GRID AI, Entero Therapeutics plans to continue its existing operations while also exploring opportunities in the AI and energy infrastructure sector.
Average Trading Volume: 1,914,419
Technical Sentiment Signal: Hold
Current Market Cap: $6.91M
See more insights into ENTO stock on TipRanks’ Stock Analysis page.